PC
MCID: PRS040
MIFTS: 94

Prostate Cancer (PC)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer

MalaCards integrated aliases for Prostate Cancer:

Name: Prostate Cancer 57 38 12 25 75 37 13 55 43 3 15 63
Prostate Cancer, Familial 57 12 76 53 73
Prostate Carcinoma 12 25 55 15 73
Prostate Neoplasm 12 25 29 6
Familial Prostate Cancer 53 59 29
Prostatic Cancer 12 25 15
Prostate Cancer, Susceptibility to 57 6
Malignant Tumor of Prostate 29 6
Hereditary Prostate Cancer 12 53
Prostate Cancer, Somatic 57 6
Prostatic Neoplasms 44 73
Prostatic Neoplasm 12 25
Prostate Cancer, Familial, Susceptibility to 57
Prostate Cancer, Susceptibility to, Somatic 57
Prostate Cancer, Susceptibility to, 4 57
Prostate Cancer, Susceptibility to, 3 57
Malignant Neoplasm of the Prostate 25
Prostate Cancer, Progression of 57
Malignant Tumor of the Prostate 12
Prostate Cancer, Hereditary, 5 57
Malignant Neoplasm of Prostate 73
Ngp - New Growth of Prostate 12
Prostate Cancer, Hereditary 53
Prostate Cancer Somatic 57
Cancer of the Prostate 25
Tumor of the Prostate 12
Carcinoma of Prostate 12
Prostatic Carcinoma 25
Cancer of Prostate 12
Prostate Cancer 4 57
Prostate Cancer 3 57
Cancer, Prostate 40
Prca 75
Pc 75

Characteristics:

Orphanet epidemiological data:

59
familial prostate cancer
Prevalence: 1-9/100000 (United States); Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant form


HPO:

32
prostate cancer:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare urogenital diseases


External Ids:

OMIM 57 176807
Disease Ontology 12 DOID:10283 DOID:10286
ICD10 33 C61
ICD9CM 35 185
MeSH 44 D011471
SNOMED-CT 68 93974005
Orphanet 59 ORPHA1331
MESH via Orphanet 45 C537243
UMLS via Orphanet 74 C2931456
ICD10 via Orphanet 34 C61
MedGen 42 C0376358
KEGG 37 H00024
SNOMED-CT via HPO 69 263681008 399068003

Summaries for Prostate Cancer

MedlinePlus : 43 The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American. Symptoms of prostate cancer may include Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling Low back pain Pain with ejaculation To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Prostate Cancer, also known as prostate cancer, familial, is related to prostate disease and breast cancer, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Cancer is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Prostate cancer and Transcriptional misregulation in cancer. The drugs Degarelix and Eligard have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are prostate cancer and cellular

Disease Ontology : 12 A male reproductive organ cancer that is located in the prostate.

Genetics Home Reference : 25 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.

NIH Rare Diseases : 53 Familialprostate cancer is a cluster of prostate cancer within a family. Most cases of prostate cancer occur sporadically in people with no family history of the condition. However, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. In many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes (mutations) in the BRCA1, BRCA2, HOXB13, or several other genes. Other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.High-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories.

CDC : 3 Prostate cancer is the most common non-skin cancer among American men. Prostate cancers usually grow slowly. Most men with prostate cancer are older than 65 years and do not die from the disease. Finding and treating prostate cancer before symptoms occur may not improve your health or help you live longer.

Novus Biologicals : 56 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

UniProtKB/Swiss-Prot : 75 Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

PubMed Health : 63 About prostate cancer: Prostate cancer develops when cells in the prostate start multiplying uncontrollably. This can happen if the genetic information (DNA) in the cells has changed (mutated). The body’s immune system usually keeps these cells in check. Cancer develops if too many mutated cells multiply and a tumor grows.The diagnosis “prostate cancer” usually comes as a shock to men and those close to them. The good news is that prostate cancer is one of the types of cancer with the best chances of recovery. This is because it often grows very slowly so it is generally possible to treat it effectively.

Wikipedia : 76 Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system.... more...

Description from OMIM: 176807

Related Diseases for Prostate Cancer

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 635)
# Related Disease Score Top Affiliating Genes
1 prostate disease 33.1 TP53 PTEN AR AKT1
2 breast cancer 31.8 TP53 PTEN PIK3CA MSR1 MIR221 MIR21
3 adenocarcinoma 31.6 TP53 PTEN PIK3CA CDH1 AKT1
4 colorectal cancer 31.4 TP53 PTEN PIK3CA MIR221 MIR21 MIR145
5 bladder cancer 31.4 TP53 MIR221 MIR21 MIR205 MIR145 CDH1
6 suppression of tumorigenicity 12 31.3 TP53 PTEN PIK3CA KLF6 CDH1 AR
7 lung cancer 31.2 TP53 PTEN POLK PIK3CA MIR221 MIR21
8 ovarian cancer 31.2 TP53 PTEN PIK3CA MIR221 MIR21 MIR146A
9 gastric cancer 31.1 TP53 PTEN PIK3CA MIR221 MIR21 MIR145
10 squamous cell carcinoma 31.1 TP53 PTEN PIK3CA MIR205 CHEK2 CDH1
11 aging 31.0 TP53 PTEN CHEK2 AKT1
12 glioblastoma 30.9 TP53 PTEN PIK3CA MIR221 MIR21 BRCA2
13 hepatocellular carcinoma 30.8 TP53 PTEN PIK3CA MIR221 MIR146A MIR145
14 meningioma, familial 30.8 TP53 PTEN CDH1 AKT1
15 pancreatic cancer 30.8 TP53 PIK3CA MIR221 MIR21 MIR205 MIR146A
16 bladder urothelial carcinoma 30.7 TP53 PIK3CA CDH1 AR AKT1
17 thyroid cancer 30.7 AKT1 CDH1 PIK3CA PTEN TP53
18 small cell cancer of the lung 30.7 TP53 PTEN PIK3CA MIR21 AKT1
19 lung cancer susceptibility 3 30.6 TP53 PIK3CA KLF6 CDH1 AKT1
20 adenoid cystic carcinoma 30.6 TP53 PTEN PIK3CA CHEK2 CDH1 AKT1
21 esophageal cancer 30.6 TP53 PTEN PIK3CA MIR21 MIR205 CHEK2
22 endometrial cancer 30.6 TP53 PTEN PIK3CA CDH1 BRCA2 AR
23 squamous cell carcinoma, head and neck 30.5 TP53 PTEN PIK3CA MIR221 MIR21 MIR205
24 cholangiocarcinoma 30.5 TP53 PTEN PIK3CA MIR21 CDH1 AKT1
25 cervical cancer 30.5 TP53 PTEN PIK3CA MIR21 CDH1 AKT1
26 glioblastoma multiforme 30.4 TP53 PTEN PIK3CA MIR221 MIR21 AKT1
27 adamantinoma of long bones 30.4 TP53 PTEN PIK3CA CDH1 BRCA2
28 glioma 30.4 TP53 PTEN PIK3CA MIR221 MIR21 BRCA2
29 cowden disease 30.4 PTEN PIK3CA MIR21 BRCA2 AKT1
30 li-fraumeni syndrome 30.4 TP53 PTEN CHEK2 BRCA2
31 breast adenocarcinoma 30.4 TP53 PTEN PIK3CA AKT1
32 cystadenocarcinoma 30.3 AKT1 PIK3CA TP53
33 carcinosarcoma 30.3 PIK3CA PTEN TP53
34 adenosquamous carcinoma 30.3 AR PIK3CA TP53
35 leukemia, acute myeloid 30.3 TP53 MIR221 MIR21 MIR146A AKT1
36 diffuse large b-cell lymphoma 30.3 TP53 MIR221 MIR21 MIR145
37 oral cancer 30.2 CDH1 MIR21 TP53
38 testicular germ cell tumor 30.2 MIR145 PTEN TP53
39 li-fraumeni syndrome 2 30.1 CHEK2 TP53
40 transitional cell carcinoma 29.9 CDH1 PTEN TP53
41 prostate cancer, hereditary, 1 12.6
42 prostate cancer, hereditary, 2 12.5
43 prostate cancer, hereditary, 13 12.5
44 prostate cancer, hereditary, 12 12.5
45 prostate cancer, hereditary, 11 12.4
46 prostate cancer, hereditary, 4 12.4
47 prostate cancer, hereditary, 7 12.3
48 adenosquamous prostate carcinoma 12.3
49 prostate cancer, hereditary, x-linked 1 12.2
50 prostate cancer/brain cancer susceptibility 12.2

Comorbidity relations with Prostate Cancer via Phenotypic Disease Network (PDN): (show all 35)


Acute Kidney Failure Anthracosis
Asbestosis Azoospermia
Balanoposthitis Bladder Cancer
Bladder Neck Obstruction Chronic Kidney Failure
Cystitis Cystica Deficiency Anemia
Disseminated Intravascular Coagulation Epididymo-Orchitis
Gout Hydronephrosis
Kidney Disease Lipoma of Spermatic Cord
Lymphadenitis Nephrolithiasis, X-Linked Recessive, with Renal Failure
Oligospermia Paralytic Ileus
Paraplegia Prostate Calculus
Prostate Carcinoma in Situ Prostate Disease
Prostatic Hypertrophy Prostatitis
Radiation Cystitis Spermatocele
Spinal Cord Disease Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to Prostate Cancer

Symptoms & Phenotypes for Prostate Cancer

Symptoms via clinical synopsis from OMIM:

57
Oncology:
early onset prostate cancer


Clinical features from OMIM:

176807

Human phenotypes related to Prostate Cancer:

32
# Description HPO Frequency HPO Source Accession
1 prostate cancer 32 HP:0012125

UMLS symptoms related to Prostate Cancer:


tremor, angina pectoris, equilibration disorder

MGI Mouse Phenotypes related to Prostate Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 AKT1 AR BRCA2 CDH1 CHEK2 KLF6
2 endocrine/exocrine gland MP:0005379 10.25 AKT1 AR BRCA2 CDH1 CHEK2 KLF6
3 homeostasis/metabolism MP:0005376 10.15 AKT1 AR BRCA2 CDH1 CHEK2 MSR1
4 hematopoietic system MP:0005397 10.1 AKT1 AR BRCA2 CHEK2 KLF6 MSR1
5 immune system MP:0005387 10.1 AKT1 AR BRCA2 CDH1 CHEK2 MSR1
6 embryo MP:0005380 10.06 AKT1 AR BRCA2 CDH1 KLF6 PIK3CA
7 mortality/aging MP:0010768 9.97 AKT1 AR BRCA2 CDH1 CHEK2 KLF6
8 integument MP:0010771 9.86 AKT1 AR BRCA2 CDH1 KLF6 PIK3CA
9 neoplasm MP:0002006 9.7 AKT1 AR BRCA2 CDH1 CHEK2 MAD1L1
10 reproductive system MP:0005389 9.36 AKT1 AR BRCA2 CDH1 KLF6 MAD1L1

Drugs & Therapeutics for Prostate Cancer

PubMedHealth treatment related to Prostate Cancer: 63

The possible treatment options for prostate cancer will depend on various factors. These include:how much the cells have changed (how aggressive the tumor is)how much the tumor has grown or spread (the stage of prostate cancer)the man’s PSA levelsindividual factors such as the man’s age, how healthy he is otherwise, and how important the pros and cons are to him.Men who have high-risk prostate cancer will usually have their prostate surgically removed or treatment with radiotherapy. Radiotherapy can be done in two ways: from outside of the body (external radiotherapy) or from inside the body (internal radiotherapy, or brachytherapy).The most common side effects of radiotherapy or removing the prostate gland are accidental leakage of urine (urinary incontinence) and erection problems (impotence). External radiotherapy is especially likely to cause diarrhea, and in some cases inflammations in the bowel which may result in blood in the stool and cramps.If the tumor is small, only inside the prostate, and not aggressive (low-risk prostate cancer), the following treatments are also possible:Active surveillance: Here the prostate cancer is simply monitored, and not treated, at first. This strategy is based on the fact that low-risk prostate cancer usually grows very slowly or doesn't grow at all. It is often found that the cancer has still not advanced even years after it was diagnosed. Instead of having treatment, the prostate is checked regularly. Treatment attempting to get rid of the cancer (curative treatment) is only started if the tumor starts growing. The advantage of this approach is that the side effects of surgery or radiotherapy can be avoided as long as the cancer does not grow. One possible disadvantage: If the cancer does progress, that is sometimes discovered too late. It may have already spread to other parts of the body by then (metastasis). Knowing that you have cancer in your body can be distressing too.Watchful waiting: This strategy also starts by only monitoring the prostate cancer at first. But if the tumor starts growing, only the symptoms are treated, not the tumor itself (this is known as “palliative care). This approach is mainly considered in older men, who may also have other medical problems. The risks and stress of surgery or radiotherapy could outweigh the possible benefits of this treatment.There is no “right” or “wrong” treatment decision for men who have low-risk prostate cancer. The strategy that one man chooses will mainly depend on his personal preferences and values. Some will feel it is more important to avoid side effects like impotence or incontinence as much as possible. Others will want to be very sure that the cancer has been removed, so they are willing to accept the risks associated with treatment.For more advanced stages of prostate cancer, there are several kinds of hormonal treatments and chemotherapies that aim to slow the growth.

FDA approved drugs:

(show all 17)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
2
Eligard 18 49 LEUPROLIDE ACETATE Atrix Laboratories January 2002
3
Eulexin 18 FLUTAMIDE Schering-Plough June 1996
4
Iressa 18 49 GEFITINIB AstraZeneca May 2003
5
Jevtana 18 49 CABAZITAXEL sanofi aventis June 2010
6
Lupron Depot 18 49 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
7
Plenaxis 18 ABARELIX Praecis Pharmaceuticals December 2003
8
Provenge 18 49 sipuleucel-T Dendreon May 2010
9
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996
10
Trelstar Depot/ Trelstar LA 18 TRIPTORELIN PAMOATE Debio Rechereche Pharmaceutique, Target Research Associates/ Debiopharm June 2000/ June 2001
11
Viadur 18 49 LEUPROLIDE ACETATE Alza March 2000
12
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
13
Xofigo 18 49 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
14
Xtandi 18 49 ENZALUTAMIDE Medivation August 2012
15
Zoladex 18 49 GOSERELIN ACETATE AstraZeneca January 1996
16
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
17
Zytiga 18 49 ABIRATERONE ACETATE Centocor Ortho Biotech May 2011

Drugs for Prostate Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 898)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 65807-02-5 47725 5311128
2
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
3
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
4
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53714-56-0 657181 3911
5
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 164656-23-9 6918296 152945
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1 2921-57-5
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
8
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 302-25-0
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
10
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-22-0 6013
11
Testosterone enanthate Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
12
Methyltestosterone Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
13
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
14
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
16
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90357-06-5 2375 56069
17
Lenograstim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
18
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
19
Histamine Approved, Investigational Phase 4,Phase 2 51-45-6, 75614-87-8 774
20
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
22
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 175805 71273
23 tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
25
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 169590-42-5 2662
26
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 9004-61-9 53477741
27
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 137-58-6 3676
28
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 615258-40-7
29
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 51110-01-1, 38916-34-6 53481605
30
Pasireotide Approved Phase 4,Phase 1,Phase 2 396091-73-9 9941444
31
Flutamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 13311-84-7 3397
32
Trimethoprim Approved, Vet_approved Phase 4,Phase 2 738-70-5 5578
33
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
34
Sulfamethoxazole Approved Phase 4,Phase 2 723-46-6 5329
35 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 7681-49-4
36
Tamsulosin Approved, Investigational Phase 4,Phase 3,Not Applicable 106133-20-4 129211
37
Finasteride Approved Phase 4,Phase 3,Phase 2,Not Applicable 98319-26-7 57363
38
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
39
Ondansetron Approved Phase 4 99614-02-5 4595
40
Diphenhydramine Approved, Investigational Phase 4,Phase 2,Phase 1 147-24-0, 58-73-1 3100
41
Ranitidine Approved Phase 4,Phase 2 66357-35-5, 66357-59-3 3001055
42
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
43
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
44
Promethazine Approved, Investigational Phase 4,Phase 2,Phase 1 60-87-7 4927
45
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
47
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
48
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
49
Desflurane Approved Phase 4 57041-67-5 42113
50
Nitric Oxide Approved Phase 4,Phase 2,Not Applicable 10102-43-9 145068

Interventional clinical trials:

(show top 50) (show all 4478)
# Name Status NCT ID Phase Drugs
1 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
2 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
3 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
4 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
5 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
6 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
7 Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial Unknown status NCT01770340 Phase 4
8 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
9 Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
10 A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer Completed NCT02116582 Phase 4 Enzalutamide
11 Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
12 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed NCT01296672 Phase 4 Finasteride;Placebo
13 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
14 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
15 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
16 A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
17 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
18 Evaluate Recovery of Testosterone for Patients Using Eligard Completed NCT01136226 Phase 4 Eligard (TM)
19 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy Completed NCT00237146 Phase 4 Zoledronic acid
20 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
21 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
22 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
23 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
24 Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Completed NCT00805701 Phase 4 avodart;Placebo
25 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
26 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
27 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
28 Casodex/Zoladex Biomarkers in Localised Prostate Cancer Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
29 Docetaxel in the Treatment of Hormone Refractory Prostate Cancer Completed NCT00280098 Phase 4 docetaxel
30 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
31 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
32 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
33 Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Completed NCT00590213 Phase 4 Casodex 150mg
34 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
35 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
36 The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
37 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
38 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4 risedronate;Placebo risedronate oral tablet
39 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
40 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4 Zoledronic acid
41 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4 Zoledronic Acid
42 Preoperative Brimonidine on IOP of Patients Undergoing RALP Completed NCT02818816 Phase 4 brimonidine tartrate 0.2%
43 Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Completed NCT00953277 Phase 4
44 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
45 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
46 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide Completed NCT02149628 Phase 4 propofol;Desflurane
47 The Use of Thermal Suits as Preventing Hypothermia During Surgery Completed NCT01571544 Phase 4
48 The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function Completed NCT01547416 Phase 4 epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose;no epidural drug administered
49 Hydroxyethyl Starch and Renal Function After Radical Prostatectomy Completed NCT01486563 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9 mg/ml
50 Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? Completed NCT00982800 Phase 4 Gabapentin;Placebo Sugar Pill

Search NIH Clinical Center for Prostate Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Prostate Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Prostate Cancer:
Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers

Cochrane evidence based reviews: prostatic neoplasms

Genetic Tests for Prostate Cancer

Genetic tests related to Prostate Cancer:

# Genetic test Affiliating Genes
1 Malignant Tumor of Prostate 29 AR BRCA2 CD82 CDH1 CHEK2 HIP1 KLF6 MAD1L1 MXI1 PTEN ZFHX3
2 Familial Prostate Cancer 29
3 Prostate Neoplasm 29

Anatomical Context for Prostate Cancer

MalaCards organs/tissues related to Prostate Cancer:

41
Prostate, Bone, Lymph Node, Testes, Lung, Endothelial, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Prostate Cancer:

19
The Prostate

Publications for Prostate Cancer

Articles related to Prostate Cancer:

(show top 50) (show all 18942)
# Title Authors Year
1
A rare case of tumor-to-tumor metastasis: Prostate cancer to chromophobe renal cell carcinoma. ( 30505689 )
2019
2
Advanced prostate cancer discovered with cancerous peritonitis: Case report. ( 30510901 )
2019
3
Osteonectin Promoter-Mediated Suicide Gene Therapy of Prostate Cancer. ( 30539527 )
2019
4
68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level. ( 30540597 )
2019
5
Mutagenesis Screens for Prostate Cancer Using Replication-Incompetent Lentiviral Vectors. ( 30542994 )
2019
6
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. ( 30546938 )
2019
7
Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. ( 30546940 )
2019
8
Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. ( 30547097 )
2019
9
Nurse-Led Supportive Care Intervention for Men With Advanced Prostate Cancer. ( 30547961 )
2019
10
MiR-1 inhibits prostate cancer PC3 cells proliferation through the Akt/mTOR signaling pathway by binding to c-Met. ( 30551391 )
2019
11
Downregulation of miR-139-5p promotes prostate cancer progression through regulation of SOX5. ( 30551470 )
2019
12
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. ( 30554605 )
2019
13
Effect of positive carbon-11-choline PET/CT results in the therapeutic management of prostate cancer biochemical relapse. ( 30521498 )
2019
14
Hypercalcemia due to parathyroid hormone-related peptide secreted by neuroendocrine dedifferentiated prostate cancer. ( 30479964 )
2019
15
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents. ( 30482547 )
2019
16
Ginsenoside Rh2 Inhibits Angiogenesis in Prostate Cancer by Targeting CNNM1. ( 30486934 )
2019
17
Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. ( 30456317 )
2019
18
MR Imaging-Guided Focal Therapies of Prostate Cancer. ( 30466907 )
2019
19
Galectin-9 induces atypical ubiquitination leading to cell death in PC-3 prostate cancer cells. ( 30383222 )
2019
20
Colorimetric detection of PCA3 in urine for prostate cancer diagnosis using thiol-labeled PCR primer and unmodified gold nanoparticles. ( 30389454 )
2019
21
Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? ( 30395048 )
2019
22
KLF14 potentiates oxidative adaptation via modulating HO-1 signaling in castrate-resistant prostate cancer. ( 30400002 )
2019
23
Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. ( 30400004 )
2019
24
The role of protein tyrosine phosphatases in prostate cancer biology. ( 30401533 )
2019
25
Is in-office transperineal biopsy the future of prostate cancer diagnosis? ( 30407219 )
2019
26
TRPM4 channel is involved in regulating epithelial to mesenchymal transition, migration, and invasion of prostate cancer cell lines. ( 30343491 )
2019
27
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. ( 30350010 )
2019
28
Robotic radical prostatectomy in a patient with prostate cancer and MERRF syndrome, a rare mitochondrial disorder affecting muscle fibers. ( 30364532 )
2019
29
Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer. ( 30365141 )
2019
30
Two prostate cancer‑associated polymorphisms in the 3'UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA binding. ( 30365147 )
2019
31
Parameter identification of a model for prostate cancer treated by intermittent therapy. ( 30292801 )
2019
32
Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer. ( 30310953 )
2019
33
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer. ( 30312731 )
2019
34
Chromium(VI) promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer. ( 30315950 )
2019
35
Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377. ( 30320363 )
2019
36
Inhibitory effects of Schisandrin B on human prostate cancer cells. ( 30320364 )
2019
37
Cartography-based quality control of prostate cancer care: a necessary ground to targeted focal therapy. ( 30320610 )
2019
38
ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer. ( 30287243 )
2019
39
Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. ( 30267117 )
2019
40
Ga-68-PSMA PET/CT in treatment-naA^ve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases? ( 29978529 )
2018
41
Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. ( 29529997 )
2018
42
Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. ( 29975957 )
2018
43
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. ( 29978216 )
2018
44
Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies. ( 29446748 )
2018
45
PPARI' Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. ( 29187400 )
2018
46
Guided undersampling classification for automated radiation therapy quality assurance of prostate cancer treatment. ( 29377156 )
2018
47
Volumetric-based image guidance is superior to marker-based alignments for stereotactic body radiotherapy of prostate cancer. ( 29450961 )
2018
48
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. ( 29293372 )
2018
49
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. ( 29979319 )
2018
50
Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. ( 27998647 )
2018